Oxford BioMedica Secures Five-Year Commercial Supply Deal with Bristol Myers Squibb for CAR-T Vector Manufacturing
Key Insights
Oxford BioMedica (search) has signed a five-year commercial supply agreement with Bristol Myers Squibb (search) to manufacture lentiviral vectors (search) for CAR-T (search) cancer therapy programs, marking a transition from clinical to commercial manufacturing.
Commercial manufacturing is expected to begin in 2026 at Oxford BioMedica (search)'s facilities in Oxford, England and Durham, North Carolina, subject to regulatory approval of the relevant CAR-T (search) products.
The expanded partnership builds on the companies' existing relationship since 2020 and is expected to generate meaningful multi-year revenue supporting Oxford BioMedica (search)'s medium-term financial guidance.
Oxford BioMedica (search) PLC has expanded its strategic partnership with Bristol Myers Squibb (search) through a new five-year commercial supply agreement for lentiviral vector manufacturing, marking a significant milestone in the transition from clinical development to commercial production of CAR-T (search) cancer therapies.
The Oxford, England-based gene and cell therapy developer will provide lentiviral vectors (search) for Bristol Myers Squibb (search)'s CAR-T (search) programs, with commercial manufacturing expected to commence in 2026 at facilities in Oxford and Durham, North Carolina. The agreement is contingent upon regulatory approval of the relevant CAR-T products.
Partnership Evolution and Commercial Transition
The latest agreement builds upon the companies' existing partnership established in March 2020. "The transition from clinical to commercial manufacturing with BMS marks an important milestone for both companies," said Sebastien Ribault, chief business officer at Oxford BioMedica (search). "Having supported these potentially life-saving CAR-T (search) programmes through development, we are confident in their commercial success and look forward to continuing our partnership with BMS."
The five-year initial term includes an option for extension, providing long-term stability for both organizations. While Oxford BioMedica (search) did not disclose specific financial details, the company indicated the contract offers potential for "meaningful multi-year revenue" in support of its existing medium-term financial guidance.
CAR-T Technology and Manufacturing
CAR-T (search) cell treatment represents a type of immunotherapy specifically designed to target blood cancers. The therapy relies on lentiviral vectors (search) to convert normal T cells (search) into CAR-T cells, which are subsequently administered to patients through chemotherapy protocols. This manufacturing process requires specialized expertise and facilities capable of producing vectors at commercial scale.
Oxford BioMedica (search)'s dual-site manufacturing approach, spanning facilities in England and North Carolina, positions the company to support global distribution of these potentially life-saving therapies once regulatory approvals are secured.
Market Response and Financial Implications
The market responded positively to the announcement, with Oxford BioMedica (search) shares rising 2.4% to 838.00 pence on Wednesday morning in London trading. The stock gained an additional 1.83% to 833p as of 0815 GMT, reflecting investor confidence in the commercial potential of the expanded partnership.
The agreement represents a strategic validation of Oxford BioMedica (search)'s manufacturing capabilities and its role in supporting Bristol Myers Squibb (search)'s CAR-T (search) portfolio as these therapies advance toward potential market approval and commercial launch.